Reviewer's report

Title: Pharmacokinetics and safety of cyclophosphamide and docetaxel in a hemodialysis patient with early stage breast cancer: a case report

Version: 3 Date: 27 January 2015

Reviewer: DJ Murry

Reviewer's report:

Major comments:
1. The analytical method performance should be included as the assay was adapted from others. Linearity, limit of detection and variability in the lab performing the assays should be reported.

2. The results include AUC from 0-infinity- however patients underwent dialysis with after hour 48. Does the AUC from 0 to infinity include the post dialysis sample? Please clarify the methods.

3. The assay the investigators used did not measure the active cyclophosphamide metabolite (4 hydroxycyclophosphamide) even though the assay they reference did – this limitation should be expanded upon and its implication to the interpretation of the data.

4. It is stated that therapy was tolerated “without severe adverse reactions” however there was grade III leukopenia. This statement should be revised to reflect this grade of toxicity and what grade toxicity would be considered severe (ie greater than grade II?) Simply because degree III toxicity occurs in 10% of patients does not mean that it is not a severe reaction.

5. Additional information about hemodialysis should be included (duration, type of filter, etc).

6. The findings for dialysis removal should be discussed with what was previously known.

Minor comments:
1. The text page 6 line 28 – auc units are uM/h, however units elsewhere are mcg/ml (figures and tables) – please be consistent with use of units – no need to convert tu uM/h in the text when concentration time plot is ug/ml (or provide the conversion).

Level of interest: An article of limited interest

Quality of written English: Needs some language corrections before being published

Statistical review: No, the manuscript does not need to be seen by a statistician.
Declaration of competing interests:

I declare that I have no competing interests